economy
February 17, 2026
Danaher is tapping the M&A well yet again. But we might have had enough
Danaher shares fell on the news that it was acquiring medtech player Masimo.
TL;DR
- Danaher agreed to acquire medtech Masimo for $9.6 billion in cash, with Masimo's stock soaring 34% on the news.
- Danaher's stock fell over 3.5% following the acquisition announcement, with Wall Street left disappointed.
- The deal's valuation multiple was considered high, and Masimo's specialty in medical technology represents a new vertical for Danaher.
- Danaher's stock has lost over 10% in 2026, extending a yearly losing streak to five consecutive years.
- Investors and analysts are expressing frustration with Danaher's performance, with discussions of potentially exiting the position.
- The acquisition is expected to be accretive to Danaher's adjusted diluted net earnings per common share.
Continue reading the original article